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Background: Extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae are often susceptible in vitro to
β-lactam/β-lactamase inhibitor (BLBLI) combination antibiotics, but their use has been limited by concerns of clinical
inefficacy. We aimed to compare outcomes between patients treated with BLBLIs and carbapenems for blood-
stream infection (BSI) caused by cefotaxime non-susceptible (likely ESBL- or AmpC β-lactamase-producing)
Escherichia coli and Klebsiella pneumoniae.
Methods: All adult patients with a BSI caused by cefotaxime non-susceptible E. coli or K. pneumoniae were included
from May 2012-May 2013. We compared outcomes between patients who had definitive monotherapy with a
carbapenem to those who had definitive monotherapy with a BLBLI.
Results: There were 92 BSIs that fulfilled the microbiological inclusion criteria. 79 (85.9%) were caused by E. coli and
13 (14.1%) by K. pneumoniae. Four out of 23 (17.4%) patients treated with carbapenem monotherapy and 2 out of
24 (8.3%) patients treated with BLBLI monotherapy died (adjusted HR for survival 0.91, 95% CI 0.13 to 6.28; p = 0.92).
The time to resolution of systemic inflammatory response syndrome (SIRS) criteria did not vary between the
treatment groups (adjusted HR 0.91, 95% CI 0.32 to 2.59; p = 0.97). The length of hospital admission post-positive
blood culture was slightly longer in patients treated with BLBLIs (median duration 15 vs. 11 days), although this was
not significant (adjusted HR 0.62; 95% CI 0.27 to 1.42; p = 0.26). There were no significant differences in subsequent
isolation of carbapenem resistant organisms (4.3% vs. 4.2%, p = 1.0), C. difficile infection (13.0% vs. 8.3%, p = 0.67) or
relapsed BSI (0% vs. 2%, p = 0.23).
Conclusions: BLBLIs appear to have a similar efficacy to carbapenems in the treatment of cefotaxime-resistant
E. coli and K. pneumoniae bloodstream infections. Directed therapy with a BLBLI, when susceptibility is proven,
may represent an appropriate carbapenem-sparing option.
Keywords: Extended-spectrum β-lactamase, Enterobacteriaceae, Piperacillin-tazobactam, Carbapenem* Correspondence: p.harris@uq.edu.au
1University of Queensland Centre for Clinical Research, Brisbane, Queensland,
Australia
2Department of Infectious Diseases, National University Hospital, Singapore,
Singapore
Full list of author information is available at the end of the article
© 2015 Harris et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Harris et al. Antimicrobial Resistance and Infection Control  (2015) 4:14 Page 2 of 10Introduction
Gram-negative bacteria that possess extended-spectrum
β-lactamase (ESBL) enzymes have emerged as a major
global public health concern in recent years [1]. When
first recognized, these resistant isolates were usually impli-
cated in nosocomially-acquired infections or outbreaks [2].
Today ESBL-producers are commonplace in the commu-
nity [3,4] or in the broader healthcare context, such as resi-
dential aged-care facilities [5,6]. The burden of disease is
particularly marked in the Asian region [7,8]. In Singapore,
approximately 20% of E. coli and 32% of Klebsiella spp. are
non-susceptible to third-generation cephalosporins [9].
Carbapenems have been regarded as the treatment of
choice for serious infections caused by ESBL-producers
[10,11]. However, the increasing worldwide incidence of
ESBL-related infections is driving increased use of carba-
penems, leading to selection pressure for carbapenem
resistance [12,13]. Even brief exposure to a carbapenem
can increase the risk of colonisation or infection with a
carbapenem-resistant organism [14]. We now face the
challenge of emerging carbapenem resistance, largely
mediated by the efficient spread of carbapenemases in
key Gram-negative pathogens [15,16]. Genes coding for
carbapenemases are usually co-located with multiple ac-
quired resistance determinants, leaving few effective, low
toxicity or non-parenteral options for therapy [17].
In the face of this rapidly changing epidemiology, there is
a pressing need to reduce carbapenem overuse. One
strategy could be re-evaluating existing agents which have
previously been considered ineffective or lack clinical data
to support their use. The β-lactam/β-lactamase inhibitor
(BLBLI) combination antibiotics, such as amoxicillin-clavu
lanate, ticarcillin-clavulanate and piperacillin-tazobactam,
have a controversial status in the treatment of infections
caused by ESBL-producers [1]. By definition, Ambler class
A ESBL enzymes are inhibited by clavulanate or tazobac-
tam in vitro and ESBL producers, especially E. coli, are
frequently susceptible to BLBLIs. Yet, there have been con-
cerns that such in vitro susceptibility may not reliably
translate into clinical efficacy [18]. This has been based
largely on concerns over inoculum effects, the co-location
of other beta-lactamase enzymes (which may not be well
inhibited by β-lactamase inhibitors) on acquired plasmids
and the potential for additional resistance mechanisms
such as alterations in outer membrane proteins [19].
Recent studies suggest that in certain situations, BLBLIs
are non-inferior to carbapenems if isolates are susceptible
in vitro, [20] especially if the minimum inhibitory concen-
tration (MIC) is low [21]. Such a strategy may represent a
reasonable carbapenem-sparing option for treating infec-
tions caused by ESBL-producers [19]. This study aimed to
examine current treatment strategies for bacteraemia
caused by cefotaxime non-susceptible Escherichia coli or
Klebsiella spp. in an institution with a relatively highincidence of ESBL-producing isolates. Increasingly,
BLBLIs are being considered for treatment of these
infections as part of antimicrobial stewardship and
carbapenem restriction. As such, we aimed to com-
pare clinical and microbiological outcomes between
patients receiving definitive carbapenem therapy with
those given piperacillin-tazobactam, as a carbapenem-
sparing treatment option.
Materials and Methods
The study has been presented in accordance with the
STROBE guidelines on the reporting of observational
studies [22].
Objectives
The aim of the study was to compare the efficacy of BLBLI
antibiotics to carbapenems for the treatment of blood-
stream infections caused by cefotaxime-resistant (likely
ESBL- or AmpC-producing) E. coli or K. pneumoniae. The
hypothesis was that there are no significant differences in
outcomes for patients treated with a BLBLI or a carba-
penem for bloodstream infections caused by cefotaxime-
resistant E. coli or K. pneumoniae, if these isolates remain
susceptible to piperacillin-tazobactam and meropenem
in vitro.
Design
A retrospective observational study examining a cohort
of patients with bloodstream infection to compare
outcomes following different antibiotic treatments.
Setting
Patients were identified from admissions to National
University Hospital (NUH), a tertiary referral hospital in
Singapore with approximately 1,068 beds. The hospital
also treats many patients from elsewhere in Asia and the
Middle-East. The prevalence of ESBL-producing isolates
is relatively high in patients presenting both from the
community and with hospital-acquired infection.
Ethics
The Domain Specific Review Board (DSRB) of the
National Healthcare Group (NHG) in Singapore pro-
vided ethics approval for this study (NHG DSRB Ref:
2013/00877).
Inclusion and exclusion criteria
Any adult patient (≥21 years) with a bloodstream infec-
tion due to E. coli or Klebsiella spp. identified through
the NUH microbiology laboratory, defined by at least
one monomicrobial positive blood culture between May
2012 to May 2013, was eligible for inclusion. Bacterial
isolates were confirmed as cefotaxime non-susceptible,
but piperacillin-tazobactam and meropenem susceptible
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they showed polymicrobial bacteraemia or if no anti-
microbial therapy was given.
Data collection
Data were obtained by clinical chart review and interroga-
tion of the electronic prescribing and laboratory informa-
tion systems. A standard clinical record form was used.
Demographic information such as age, date of hospital ad-
mission and ethnicity were recorded. Community, hospital
and healthcare acquisition of bloodstream infection was
defined according to standard criteria (defined below)
[24]. Concurrent co-morbidities defined at admission were
recorded (see Additional file 1). The presence of a medical
device in the 7 days prior to bloodstream infection was
recorded; this included vascular catheters (peripherally
inserted central catheter [PICC], dialysis catheter, central
venous catheter or implanted line), central nervous system
devices (e.g. external ventricular drain) and urinary cathe-
ters or nephrostomy tubes. Relevant therapy in the 30
days prior to bloodstream infection was documented, in-
cluding cytotoxic chemotherapy, systemic corticosteroids
(>15 mg of prednisolone daily or equivalent), anti-TNF
(tumour necrosis factor) therapy in last 12 months, other
monoclonal antibody therapy, use of immune suppressive
agents or radiation therapy. Any surgery in 14 days prior
to first blood culture was also recorded. All enrolled pa-
tients were stratified using the Charlson co-morbidity
index (CCI) using pre-specified definitions (see supple-
mentary material) [25]. Patients admitted to the intensive
care unit (ICU) were also assessed using APACHE II
scores [26]. Pitt bacteraemia scores were calculated based
on clinical parameters measured within 24 hours of initial
blood culture collection [27].
The probable source of bacteraemia was assessed
according to the available clinical and microbiological
information and classified by the investigators using the
following categories: urinary tract, central nervous sys-
tem, pneumonia, intra-abdominal, hepato-biliary, muco-
sitis, line related, musculoskeletal, skin and soft tissue
(including burns), surgical site infection, neutropenic
sepsis, other or unknown source.
Acquisition status
Acquisition status was defined as follows, in accordance
with standard criteria [24]:
1. Hospital-acquired infection (HAI): afebrile on
admission, blood culture positive >48 h after
admission or within 48 h after discharge.
2. Community onset: blood culture collected <48 h
after admission, not admitted or >48 h after
discharge; then defined as healthcare associated if
any of the following:a. Hospitalisation (excluding natural birth) for 2 or
more days within 90 days or attendance at
emergency department within 2–30 days before
bloodstream infection
b. Admission to an out-patient intravenous therapy
or hospital-in-the-home service within 2–30 days
before bloodstream infection
c. Chronic renal dialysis
d. Residence in long-term care facility
3. Community associated: none of the above
Antibiotic use
Therapy was defined as empirical if the first dose was given
within the first 72 hours following blood culture collection,
before results of blood cultures were available (including
susceptibility testing); definitive therapy was defined if initi-
ated > 72 h following initial blood culture collection and
for ≥50% of the total treatment duration. All Gram-
negative active agents administered were recorded, includ-
ing doses, frequency and duration in days. Prescribing data
were collected using the hospital electronic prescribing sys-
tem. Adequate empirical therapy was defined as the receipt
of at least one parenteral agent (or oral agent with good
bioavailability, such as a fluoroquinolone) to which the
isolate was subsequently found to be susceptible in vitro.
Intravenous doses of piperacillin-tazobactam 4.5 g 6-hourly
or 8-hourly, amoxicillin-clavulanate 1.2 g 8-hourly, mero-
penem 1 g 8-hourly, ertapenem 1 g 24-hourly or imipenem
500 mg 6-hourly were used (with adjustment for renal
dysfunction) as per local prescribing guidelines.
Vital sign measurement
Maximum and minimum temperatures (Tmax and Tmin),
maximal heart rate, maximal respiratory rate, highest
total white cell count (if tested), lowest systolic blood
pressure, use of a vasopressor agent and results of any
repeat blood cultures (if collected) were recorded daily
for seven days.
Outcome measures
1. Days to resolution of systemic inflammatory
response syndrome (SIRS). SIRS was defined as
being present if ≥2 of the following were recorded:
a. Tmax >38°C or Tmin < 36°C
b. Lowest systolic blood pressure <90 mmHg and/or
inotrope requirement,
c. Respiratory rate >20/min or arterial PaCO2 < 32 mm
Hg if ventilated,
d. Maximal heart rate >90/min,
e. Total white cell count >12 × 109/L or <4 × 109/L
Days to resolution of SIRS was calculated from the
date of initial blood culture collection to the first
Table 1 Susceptibility profiles of E. coli or K. pneumoniae isolated from blood cultures with resistance to ceftriaxone
during study period
Susceptibility category Antimicrobial agent tested
E. coli AMP AMC TZP CXM CRO CTX CAZ FEP FOX IPM MEM ETP LVX CIP SXT GEN AMK
R (%) 100 60 0 100 100 100 96 0 11 0 0 0 71 71 59 35 0
I (%) 0 0 0 0 0 0 4 4 20 0 0 0 0 3 0 0 3
S (%) 0 40 100 0 0 0 0 96 68 100 100 100 29 27 41 65 97
Total tested 79 73 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79
K. pneumoniae
R (%) 100 45 0 100 100 100 100 92 0 0 0 0 15 30 85 31 0
I (%) 0 0 0 0 0 0 0 8 8 0 0 0 0 40 0 0 0
S (%) 0 55 100 0 0 0 0 0 92 100 100 100 85 30 15 69 100
Total tested 13 11 13 13 13 13 13 13 13 13 13 13 13 10 13 13 13
R = resistant, I = intermediate, S = susceptible; AMP = ampicillin, AMC = amoxicillin-clavulanate, TZP = piperacillin-tazobactam, CXM = cefuroxime, CRO = ceftriaxone,
CTX = cefotaxime, CAZ = ceftazidime, FEP = cefepime, FOX = cefoxitin, IMP = imipenem, MEM=meropenem, ETP = ertapenem, LVX = levofloxacin, CIP = ciprofloxacin,
SXT = trimethoprim-sulphamethoxazole, GEN = gentamicin, AMK = amikacin.
Table 2 MIC distributions for cefotaxime-resistant and
piperacillin-tazobactam susceptible E. coli and K.
pneumoniae from blood culture isolates tested by Vitek2
AMC MIC N (%) FOX MIC N (%) TZP MIC N (%)
4 19 (21.8) <=4 60 (72.3) <=4 65 (70.7)
8 19.0 (21.8) 8 6 (7.2) 8.0 27.0 (29.3)
16 32 (36.8) 16 8 (9.6) - -
> = 32 17 (19.5) 32 9 (10.8) - -
- - > = 64 9 (10.8) - -
Total 87 83 92
AMC = amoxicillin-clavulanate, FOX = cefoxitin, TZP = piperacillin-tazobactam.
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(as defined above). Patients were assumed to have
resolution of SIRS on the date of discharge (if they
did not have resolution of SIRS previously using the
above criteria). Patients who died were included in
the analysis, and defined as never having resolution
of SIRS. Where daily white cell count values were
missing, the value was imputed by calculating the
midpoint difference between the adjacent day values.
Patients for whom SIRS criteria could not be
ascertained due to missing data were excluded
from this part of the analysis.
2. All-cause mortality at 30 days post initial positive
blood culture.
3. Identification of a carbapenem or piperacillin-
tazobactam resistant isolate in subsequent 30 days
or identification of Clostridium difficile infection.
4. Microbiological relapse (positive blood culture >72 h
after initiation of definitive therapy and up to 30 days)
with same organism as original initial blood culture.
5. Length of hospital stay post first positive blood culture.
Patients who died were excluded from this analysis.
Microbiological testing
Blood cultures were inoculated into BacT/Alert bottles
(BioMerieux; Marcy-L’Étiole, France) and incubated for
up to 5 days. Positive cultures were sub-cultured and iden-
tified to species level by standard laboratory methods, in-
cluding MALDI-TOF (Bruker Daltoniks GmHB; Bremen,
Germany) and Vitek2 (BioMerieux). Susceptibility testing
was performed using Vitek2 microbroth dilution accord-
ing to EUCAST interpretative standards [23]. Phenotypic
testing or molecular methods were not routinely used to
confirm ESBL or plasmid-mediated AmpC beta-lactamase
production. Antibiotic reporting was at the discretion of
the duty microbiologist at the time of the bloodstreaminfection. All positive blood cultures reported within the
30-day follow-up period were also recorded.Statistical analysis
Categorical data were presented as proportions and scale
data using median and interquartile ranges. Patients who
received carbapenems or BLBLIs as definitive monother-
apy were identified and compared. Groups given other
non-carbapenem or non-BLBLI therapy and combination
therapy were excluded. Survival curves for mortality, days
to resolution of SIRS, and length of hospital stay were
presented using Kaplan-Meier curves. Cox proportional
hazards regression was used to assess potential con-
founders identified a priori (age, acquisition status, Pitt
bacteraemia score, ICU admission, organism, and whether
or not the patient had received appropriate empirical
therapy). Potential confounders were included in the final
regression model if they caused a change in the main ef-
fect (hazard ratio according to definitive treatment) by 5%
or more when included in bivariate analysis with definitive
treatment. Statistical analysis was performed using Stata
(StataCorp; Texas, USA).
Table 3 Baseline characteristics of patients given














77 [61–83] 77 [68–83] 75 [62–83]
Female 13 (54%) 12 (52%) 49 (54%)
Hospital acquired 7 (29%) 4 (17%) 20 (22%)
Community acquired 7 (29%) 9 (39%) 42 (46%)
Healthcare associated 10 (42%) 10 (43%) 29 (32%)
CCI, median [IQR] 2 [1-4] 2 [1-5] 2 [1-4]
Pitt score, median [IQR] 1 [0–2] 1 [0–3] 1 [0–2]
APACHEII (if ICU),
median [IQR]
26 20 24 [15-28]
ICU admission 2 (8%) 5 (22%) 11 (12.1)
E. coli 22 (92%) 17 (74%) 79 (87%)
Source:
Hepato-biliary 2 (8%) 2 (9%) 12 (13%)
Urinary tract 9 (38%) 13 (57%) 43 (47%)
Neutropenic sepsis 1 (4%) 0 (0%) 4 (4%)




3 (13%) 1 (4%) 7 (8%)
Diabetes without end
organ damage
6 (25%) 5 (22%) 21 (23%)
Diabetes with organ
damage
4 (17%) 5 (22%) 15 (17%)
Moderate to severe
renal disease
4 (17%) 7 (31%) 19 (21%)
Metastatic solid tumour 1 (4%) 1 (4%) 4 (4%)
Leukaemia or lymphoma 1 (4%) 2 (9%) 7 (8%)
Urinary device 5 (21%) 3 (13%) 15 (17%)
Immunosuppressive
treatments
2 (8%) 4 (17%) 12 (13%)
Empirical therapy:
3GC 7 (29%) 6 (26%) 33 (36%)
BLBLI 11 (46%) 5 (22%) 25 (28%)
Carbapenem 0 (0%) 2 (9%) 8 (9%)
Other* 6 (25%) 10 (43%) 25 (27%)
Appropriate empirical
therapy
15 (63%) 15 (65%) 50 (55%)
*Including combinations of carbapenem/BLBLI/3CG.
CCI = Charlson Co-morbidity index, IQR = Inter-quartile range, ICU = intensive
care unit, 3GC = third-generation cephalosporins,
BLBLI = beta-lactam/beta-lactamase inhibitor.
Harris et al. Antimicrobial Resistance and Infection Control  (2015) 4:14 Page 5 of 10Results
During the period from May 2012 to May 2013 there were
there were 476 E. coli and 328 K. pneumoniae blood-
stream infections in patients > =21 years old. Out of the
total 804 bloodstream infection events, there were 92
(11.4%) that fulfilled the microbiological inclusion criteria,
of which 79 (85.9%) were caused by E. coli and 13 (14.1%)
by K. pneumoniae. Susceptibility patterns are summarized
in Table 1 and MIC distributions for amoxicillin-
clavulanate, piperacillin-tazobactam and cefoxitin are
shown in Table 2. One patient was excluded as they were
discharged without any antibiotic treatment. The median
age was 75 years (range 23–100 years; IQR 21) and 53.8%
were female. Of the 91 patients given treatment, 44 re-
ceived definitive treatment that did not include a BLBLI
or a carbapenem or were given combination definitive
therapy, leaving 47 patients eligible for inclusion in the
analysis for definitive therapy (24 receiving a BLBLI and
23 a carbapenem) (see Figure 1). Definitive carbapenem
monotherapy included 60.9% given meropenem, 34.8%
imipenem and 4.3% ertapenem; for definitive monother-
apy with a BLBLI, 95.8% were given piperacillin-tazo
bactam and 4.2% amoxicillin-clavulanate. In the carba-
penem treated group, 17.4% received ‘step-down’ once
daily therapy with ertapenem following initial therapy with
imipenem or meropenem. In the BLBLI treated group,
8.3% were given ‘step-down’ therapy with amoxicillin-
clavualante following piperacillin-tazobactam. Other anti-
biotic choices, along with the baseline characteristics are
reported in Table 3. Mortality was relatively infrequent:
four out of 23 (17.4%) patients treated with carbapenem
monotherapy and 2 out of 24 (8.3%) patients treated with
BLBLI monotherapy (Figure 2). On univariate analysis of
mortality, a non-significant result favouring BLBLIs was
seen, but this was diminished after adjustment for con-
founders (see Table 4). The HR for survival at 30 days was
0.91 (95% CI 0.13 to 6.28; p = 0.92) after adjustment for
ICU admission, infecting organism, and Pitt score. There
was no difference in the time to resolution of SIRS
between the two definitive treatment groups (HR 0.91,
95% CI 0.32 to 2.59; p = 0.97) (Figure 3 and Table 4). For
the analysis of the length of hospital stay post positive
blood culture, four patients were excluded because they
had prolonged hospital admission (>40 days) due to unre-
lated factors. The length of hospital stay post positive
blood culture was slightly longer in patients treated with
BLBLI compared to carbapenem. For those treated with a
BLBLI, the median length of stay was 15 days [IQR 10 to
19 days] while for those given a carbapenem, the median
length of stay was 11 days [IQR 8 to 20 days]. In the Cox
regression analysis, this difference was not statistically sig-
nificant (HR 0.62, 95% CI 0.27 to 1.42; p =0.26) (Figure 4
and Table 4). There were no significant differences in sub-
sequent isolation of a carbapenem resistant organism(4.3% vs. 4.2%, p = 1.0), C. difficile infection (13.0% vs.
8.3%, p = 0.67) or relapsed bloodstream infection (0% vs.
2%, p = 0.23).
Figure 1 Patient inclusion flowchart - treatment with BLBLI or carbapenem.
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In this retrospective observational study, use of a BLBLI
as definitive monotherapy for the treatment of cefotaxime
non-susceptible E. coli or K. pneumoniae bloodstream
infection was not associated with worse outcome when
compared to the use of a carbapenem – often considered
standard therapy for such infections [10]. Not only were
there no significant differences in 30-day mortality, but
there were also no differences in resolution of SIRS cri-
teria over 7 days post bacteraemia. Although event rates





















Figure 2 30-day mortality for patients treated with BLBLI or carbapenem arelapsed bacteraemia, C. difficile infection or subsequent
isolation of a multi-resistant organism. There was a trend
towards a longer length of hospital stay in the BLBLI-
treated group; although this was not significant (the Cox
regression analysis of the length of hospital stay had a
power of 55% to detect a hazard ratio of 0.5).
These findings are broadly similar to a prospective
study addressing this question from Rodriguez-Bano
et al. [20] and a meta-analysis that examined studies that
reported outcomes for patients treated with BLBLIs for





Table 4 Results of Cox regression analyses
Outcome Definitive treatment n Crude hazard ratio (95% CI) Adjusted hazard ratio (95% CI)
30 day mortality Carbapenem 20 1 1
BLBLI 21 0.47 (0.09 to 2.59) 0.91 (0.13 to 6.28)*
Resolution of SIRS Carbapenem 14 1 1
BLBLI 14 1.19 (0.44 to 3.19) 0.91 (0.32 to 2.59)*
Hospital discharge Carbapenem 16 1 1
BLBLI 16 0.74 (0.38 to 1.41) 0.62 (0.27 to 1.42)*
*Adjusted for ICU admission, infecting organism, Pitt score.
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patients given BLBLIs when compared with carbapen-
ems for empirical or definitive therapy. As such, these
studies would support the concept that BLBLIs, at least,
represent a safe carbapenem-sparing option when sus-
ceptibility is proven, despite the likely presence of a
broad-spectrum beta-lactamase.
Limitations of the study are acknowledged. The total
patient cohort was relatively small, especially in the de-
finitive treatment cohort receiving monotherapy with a
BLBLI or carbapenem. A significant proportion of pa-
tients received either sequential monotherapy with dif-
ferent agents, or various combination therapies, and so
were excluded from the analysis thus reducing the sam-
ple size. As such, the study was underpowered to detect
true differences in infrequent outcomes, particularly for
mortality at 30 days. Given the retrospective nature of
the study, potential confounders are likely. These might
include the propensity to receive a carbapenem (which
may occur in patients with a higher risk of mortality) po-
tentially over-estimating the relative efficacy of BLBLIs.
We have adjusted for several potential confounding fac-


























Figure 3 Days to recovery from SIRS (<2 SIRS criteria or discharge).from these factors, or confounding from other unmeas-
ured factors, may remain. Although Pitt scores are pre-
dictive for mortality in bloodstream infection, additional
measures (such as the presence of septic shock or other
markers of illness severity at presentation) may have pro-
vided further information on potential confounders, but
were not available.
Resistance to third-generation cephalosporins, using
current EUCAST criteria, is a sensitive but not highly
specific marker for ESBL-production. Plasmid-mediated
AmpC beta-lactamase acquisition has become widespread
in recent years in these species and may provide a similar
resistance profile, although are usually also resistant to
cefoxitin (in contrast to ESBL-producers). This is of rele-
vance because AmpC enzymes are less effectively inhib-
ited by tazobactam, which could limit clinical efficacy. In
this study we were not able to confirm the beta-lactamase
types in blood culture isolates. However, amongst E. coli
and K. pneumoniae, 31% and 8% respectively tested non-
susceptible (resistant or intermediate) to cefoxitin, sug-
gesting that plasmid-AmpC may occur frequently within
E. coli in this population. However, ESBLs may themselves
cause elevated MICs to cefoxitin, so extrapolation from3 4 5 6
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Days following positive blood culture
Carbapenem BLBLI
Definitive treatment
Figure 4 Length of hospital admission post-positive blood culture for patients treated with BLBLI or carbapenem as definitive monotherapy.
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≥32 μg/mL has been suggested as a useful screening
marker for selecting isolates for confirmatory tests of
AmpC production [29]. It is also acknowledged that MIC
determination with the Vitek2 instrument, as used in this
study, is not a reference method. In common with several
other countries, the predominant ESBLs found in Entero-
bacteriaceae in Singapore are CTX-M types, but plasmid-
mediated AmpC-producers are increasingly seen [30,31].
In an ongoing study using whole genome sequencing to
characterise third-generation cephalosporin-resistant but
piperacillin-tazobactam susceptible E. coli or K. pneu-
moniae from BSIs in Singapore, CTX-M-type ESBLs
predominated (found in more than 85% of isolates) al-
though plasmid-mediated AmpC (CMY- or DHA-like)
β-lactamases were present in around 10% (in-house un-
published data). There has also been a marked increase
in the numbers of isolates with acquired carbapene-
mases in Singapore, [32] highlighting the need to define
alternatives to carbapenems where possible.
Further work is needed to definitively test the concept
that BLBLIs are, in general, a safe and effective
carbapenem-sparing option for the treatment of blood-
stream infections caused by third-generation cephalos
porin-resistant E. coli or K. pneumoniae. A large inter-
national retrospective observational study has recently
reported similar findings to this study [33]. However,
studies of this nature are always prone to bias, leaving
ongoing uncertainty as to the clinical efficacy of BLBLIs
against ESBL-producers. There also remains debate over
the effect of MICs that fall in the higher end of the
susceptible range, especially for infection outside the
urinary tract [34]. A recent retrospective study com-
pared the empirical use of piperacillin-tazobactam withcarbapenems for bloodstream infections caused by
ESBL-producers, and reported an adjusted risk of death
in patients given piperacillin-tazobactam as 1.92 times
higher than those given carbapenem therapy (95% CI,
1.07-3.45) [35]. As such, there exists considerable uncer-
tainty in the role of BLBLIs for the treatment of blood-
stream infection caused by ESBL-producers. Ideally,
such questions should be answered in a randomised
controlled trial. Such a study is now underway across
several Australasian sites, including Singapore (the
‘MERINO’ trial, registered at www.clinicaltrials.gov;
NCT02176122) and aims to be completed by 2018.
Conclusions
In this retrospective study, comparable outcomes were
seen for patients given definitive treatment with BLBLIs
or carbapenems for bloodstream infections caused by
cefotaxime non-susceptible E. coli or K. pneumoniae in
terms of all-cause mortality, resolution of SIRS, length of
stay or bacteraemia relapse. There were also no signifi-
cant differences in subsequent infection or colonisation
with a multi-resistant organism or C. difficile infection.
However, larger studies adequately powered to detect
differences in mortality, preferably in the form of multi-
centre randomised trials, are needed before such a strat-
egy can be recommended as standard care.
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